WO1997001563A1 - Cristaux de benzoates bicozamycine stables - Google Patents
Cristaux de benzoates bicozamycine stables Download PDFInfo
- Publication number
- WO1997001563A1 WO1997001563A1 PCT/JP1996/001605 JP9601605W WO9701563A1 WO 1997001563 A1 WO1997001563 A1 WO 1997001563A1 JP 9601605 W JP9601605 W JP 9601605W WO 9701563 A1 WO9701563 A1 WO 9701563A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- crystals
- benzoate
- type
- stable
- vicosamycin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
Definitions
- the present invention relates to a novel and stable crystal of vicosamycin benzoate and a method for producing the same.
- Bicozamycin benzoate is a known substance (see, for example, JP-A-48-39497, U.S. Pat. No. 3,923,790, International Publication No. W094Z17073), and is currently sold as a marine medicine In addition, development as a terrestrial veterinary drug is being actively pursued.
- crystal forms of vicosamycin benzoate include 020 type (stable type), 015 type (metastable type), F01 type (the above-mentioned JP-A-48-39497) and an amorphous type.
- 020 type stable type
- 015 type metal-stable type
- F01 type the above-mentioned JP-A-48-39497
- amorphous type it is desirable to obtain a 020 type crystal from the viewpoints of yield, quality, and crystal handling as described below.
- the crystallization loss can be reduced because the solubility is smaller than that of the 015 type crystal.
- the specific volume is small, the number of batches during drying is small, and the schedule can be shortened and the number of operating personnel can be reduced.
- the 020 type crystal has the following advantages as compared with the conventional F01 type crystal. (1) Because it is stable without moisture absorption, it is easy to handle crystals under scale-up conditions.
- a challenge is to produce a stable crystal form of bicosamycin benzoate (type 020) with high purity and high yield.
- the present invention is characterized in that crude crystals of vicosamycin benzoate are dissolved in aqueous alcohol, and then crystals or powder of vicosamycin benzoate are added as seed crystals, followed by crystallization at a temperature of 3 ° C. or more. It is intended to provide a novel and stable crystal of kozamycin benzoate and a method for producing the same.
- the production of novel and stable crystals of bicozamycin according to the present invention is carried out by dissolving the crude crystals of bicozamycin besoleate in aqueous alcohol, and the aqueous alcohol includes methanol, ethanol, propanol, isopropanol, and the like.
- An aqueous solution such as butanol may be used.
- the concentration of the hydrous alcohol may be any concentration at which the bicozamycin benzoate is completely dissolved. ) May be in the concentration range of 20 to 40%.
- a crystal or powder of vicosamycin benzoate is added as a seed crystal to the solution of vicosamycin benzoate and crystallized at a temperature of 3 ° C or more.
- the crystal form of vicosamycin benzoate used as a seed crystal is not limited. (020 type, 015 type, amorphous type, etc.) or powder.
- crystallization is performed by lowering the alcohol concentration in the solution by adding water. In the case of isopropanol, about 16% is best.
- the crystallization temperature is 3 ° C. or higher for hydrated isopropanol, preferably
- the crystal (type 020) thus obtained has the following properties.
- the reaction-terminated liquid was transferred to a 500 ml 3-face corvene, diluted with 125 ml of ethyl acetate, diluted with 75 ml of normal heptane at room temperature, and stirred for 1 hour to precipitate the desired crystal. Then, 175 ml of normal heptane was added dropwise over 30 minutes, and the mixture was further stirred for 1 hour. The precipitated crystals were filtered and washed successively with 50 ml of a mixture of ethyl acetate and normal heptane (1: 1) and 7.5 ml of water. Then, the crystals were dried under vacuum to obtain crude crystals of vicosamycin benzoate 34.5.
- the lysate was clarified, and the 300 ml 3 face colben and the vessel were washed with 42 ml of water.
- the clarified solution and washing solution are stored in a 500 ml 3 ml corven and kept at 3-5 ° C. And cooled.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
L'invention concerne des cristaux de benzoate de bicozamycine stables et un procédé pour les produire.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP15901095 | 1995-06-26 | ||
| JP7/159010 | 1995-06-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1997001563A1 true WO1997001563A1 (fr) | 1997-01-16 |
Family
ID=15684279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP1996/001605 WO1997001563A1 (fr) | 1995-06-26 | 1996-06-13 | Cristaux de benzoates bicozamycine stables |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO1997001563A1 (fr) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4839497A (fr) * | 1971-10-01 | 1973-06-09 |
-
1996
- 1996-06-13 WO PCT/JP1996/001605 patent/WO1997001563A1/fr active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4839497A (fr) * | 1971-10-01 | 1973-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4138886B2 (ja) | ２−アミノ−４−（４−フルオルベンジルアミノ）−１−エトキシカルボニル−アミノベンゼンの新規変態ならびにその製造法 | |
| JPH05208943A (ja) | Ｎ−（トランス−４−イソプロピルシクロヘキシルカルボニル）−ｄ−フェニルアラニンの結晶及びその製造法 | |
| KR102522895B1 (ko) | Jak 키나아제 억제제 바이설페이트의 결정형 및 이의 제조방법 | |
| JP3726291B2 (ja) | 安定な結晶構造を有するベンゾオキサジン化合物およびその製造法 | |
| WO2018117267A1 (fr) | Sel de composé pipéridine substitué | |
| WO2021116074A1 (fr) | Forme cristalline d'un dérivé d'acide 7h-benzo[7]annulène-2-carboxylique | |
| WO2012022240A1 (fr) | Nouveau cristal d'erlotinib sous forme de base et son procédé de préparation | |
| CN103755723B (zh) | 一种利福平i晶型的制备方法 | |
| CN114008023A (zh) | 索吡溴铵的晶型及其制备方法 | |
| AU2001265377A1 (en) | Crystal modification of fexofenadine | |
| WO2001094313A2 (fr) | Modification cristalline | |
| EP3094637B1 (fr) | Formes solides de ténofovir | |
| CN112028896A (zh) | 阿卡替尼的新晶型及其制备方法 | |
| RU2586117C2 (ru) | Кристаллизация гидрохлорида эпирубицина | |
| KR20050033525A (ko) | 가바펜틴의 새로운 무수 결정질 형태 | |
| WO1997001563A1 (fr) | Cristaux de benzoates bicozamycine stables | |
| EA008055B1 (ru) | Кристаллические формы оланзапина и способы их получения | |
| JP6761564B2 (ja) | ナトリウム・グルコース共輸送体２阻害薬のｌ−プロリン化合物、およびｌ−プロリン化合物の一水和物および結晶 | |
| CN110372635B (zh) | 氢溴酸沃替西汀α晶型的制备方法 | |
| WO2017167949A1 (fr) | Formes cristallines de bilastine | |
| WO2019211870A1 (fr) | Formes polymorphes d'ibrutinib | |
| WO2018233273A1 (fr) | Procédé industriel permettant de préparer un cristal de type aiguille de dicycloplatine à haute pureté | |
| WO2020004358A1 (fr) | CRISTAL D'HYDRATE DE 3',3'-cGAMP | |
| WO2021134921A1 (fr) | Forme cristalline de flazasulfuron et son procédé de préparation | |
| US20050272802A1 (en) | Process for preparing form I of tegaserod maleate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA CN JP KR US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: CA |